Preclinical News and Research

RSS

Children could be saved from neuroblastoma using antibody therapy

Combination of T cell, antibody to neuroblastoma cells and molecule that spurs T cell growth is designed to treat low initial tumor levels or small cancer cell populations that survive initial treatment, according to St. Jude.

22 Dec 2005

Common garden plant may hold cure for leukemia

Scientists in the U.S. believe they have identified a new pathway in the progression of chronic myelogenous leukemia (CML).

12 Dec 2005

Study suggests a way to eliminate glioblastoma

Scientists have devised a strategy to treat tumors by selectively targeting and killing the malignant cells. A new preclinical study, published in the open access journal PLoS Medicine, has applied the approach to combat glioblastoma multiforme (GBM).

7 Dec 2005

Phenoxodiol - docetaxel combination for women with recurrent ovarian cancer

A clinical study of ovarian cancer initiated by investigators at Yale School of Medicine will combine the anti-cancer drug phenoxodiol with docetaxel for women with recurrent ovarian cancer.

5 Dec 2005

Compound from Salinispora (marine bacteria) kills blood cancer cells

An anti-cancer compound derived from bacteria dwelling in ocean-bottom sediments appears in laboratory tests to be a potent killer of drug-resistant multiple myeloma cells, and potentially with less toxicity than current treatments, report Dana-Farber Cancer Institute researchers in the November issue of Cancer Cell.

21 Nov 2005

Plant extract forskolin may lead to leukemia treatment

Scientists here have identified a new pathway in the progression of chronic myelogenous leukemia (CML). They also discovered that an extract from the root of a common ornamental plant can suppress the process.

20 Nov 2005

Introgen's INGN 241 combined with Celebrex kills breast cancer cells

Introgen Therapeutics, Inc. today reported the publication of preclinical data demonstrating that INGN 241 works synergistically with celecoxib (Celebrex) marketed by Pfizer to inhibit the growth and increase apoptosis (cell death) of breast cancer cells.

8 Nov 2005

Research project to advance understanding of how cancer cells evade the immune system

A pre-clinical research project coordinated by The University of Manchester, which will advance understanding of how cancer cells evade the immune system, has been awarded nearly 12m Euro by the EU.

From The University of Manchester 7 Nov 2005

Calcitriol - promising chemopreventive agent that may prevent prostate cancer

The active metabolite of vitamin D, calcitriol, and other vitamin D analogs are promising chemopreventive agents that may prevent prostate cancer, according to a study presented today at the American Association for Cancer Research's 4th annual Frontiers in Cancer Prevention Research meeting in Baltimore.

3 Nov 2005

Nearly one-fourth of all dialysis patients have a close relative on dialysis

Researchers at Wake Forest University Baptist Medical Center, and others, report in the current online edition of the American Journal of Nephrology. The researchers suggest screening other relatives for undetected kidney disease.

3 Nov 2005

More exercise equals lower risk of ischemic stroke

Even in an Asian nation where people generally have higher levels of physical activity on the job than is typical in North America or Europe, those who walk more or engage in regular sports activity tend to have lower levels of ischemic stroke and coronary heart disease

27 Oct 2005

New treatment for the pediatric eye cancer retinoblastoma

Investigators at St. Jude Children's Research Hospital have demonstrated in laboratory studies a new treatment for the pediatric eye cancer retinoblastoma that appears to be more effective than the current standard therapy, and more likely to prevent the recurrence of this cancer. A report on their work appears in the October 15 issue of Clinical Cancer Research.

17 Oct 2005

Myriad Genetics nears completion of antithrombin drug trial

Myriad Genetics announced today that it is rapidly nearing completion of the preclinical data package on MPC-0920, its antithrombin drug candidate, for submission to the FDA prior to beginning human clinical trials.

11 Oct 2005

Johns Hopkins awarded $12 million to study how stem cell therapies can be used to treat hearts damaged by heart attack

Heart specialists at Johns Hopkins Heart Institute have been awarded more than $12 million from the National Heart, Lung, and Blood Institute (NHLBI) to study how stem cell therapies can be used to treat hearts damaged by heart attack or heart failure.

4 Oct 2005

New treatment option for chronic sinusitis

Acclarent on Saturday unveiled their new treatment option for chronic sinusitis, the Balloon Sinuplasty procedure. Results from the initial safety and feasibility study of this unique, catheter-based treatment for chronic sinusitis were presented by William Bolger, MD, FACS.

26 Sep 2005

Microchip system aims to reduce the number of animals used in the development of new drugs

Reducing the number of animals used in the development of new drugs is a priority for the pharmaceutical industry

26 Sep 2005

Neurologix announces positive interim results of gene therapy clinical trial for patients with Parkinson's disease

Neurologix has announced positive interim results of its landmark gene therapy clinical trial for patients with Parkinson's disease. Neurologix's 12-patient, dose-escalating Phase I trial is the world's first study to use a viral vector (the non-pathogenic adeno-associated virus, or AAV) for the treatment of an adult neurological disease.

26 Sep 2005

First true animal model for psoriasis

Scientists at the Research Institute of Molecular Pathology in Vienna have developed the first true animal model for psoriasis and have been able to address the initial steps and possible causes of the disease.

20 Sep 2005

Molecular pathway in mice that makes prostate cells vulnerable to cancer-causing oxygen damage

Scientists from Maryland and New Jersey have identified a molecular pathway in mice that makes prostate cells vulnerable to cancer-causing oxygen damage.

19 Sep 2005

RNAi therapeutic successful for treatment of SARS respiratory virus in Rhesus Macaque

Intradigm Corporation announced today its collaboration with Chinese academic and biotech groups has achieved clear evidence of prophylactic and therapeutic effects of siRNA (small interfering RNA) agents in Rhesus monkey to treat SARS coronavirus (SCV) respiratory infection.

12 Sep 2005